Glucose

Generic Name: Glucose

Brand Names: Bss Ophthalmic Solution, Citrasate, Clinimix 2.75/5, Clinimix E 2.75/5, Dextroject, Dianeal, H.E.L.P.bicel, Hemosate Ultra, Lactate 1-2-3, Leukotrap, Naturalyte, Nauzene, Normosol-R, Nxstage Pureflow, Olimel, Periolimel, Physioneal 40, Sag-M, Sclerodex, Selectbag One

Drug Type: Small Molecule

Unique Ingredient Identifier: IY9XDZ35W2

Background: Glucose is a simple sugar (monosaccharide) generated during phosynthesis involving water, carbon and sunlight in plants. It is produced in humans via hepatic gluconeogenesis and breakdown of polymeric glucose forms (glycogenolysis). It circulates in human circulation as blood glucose and acts as an essential energy source for many organisms through aerobic or anaerobic respiration and fermentation. It is primarily stored as starch in plants and glycogen in animals to be used in various metabolic processes in the cellular level. Its aldohexose stereoisomer, dextrose or D-glucose, is the most commonly occurring isomer of glucose in nature. L-glucose is a synthesized enantiomer that is used as a low-calorie sweetener and laxative. The unspecified form of glucose is commonly supplied as an injection for nutritional supplementation or metabolic disorders where glucose levels are improperly regulated. Glucose is listed on the World Health Organization's List of Essential Medicines.

Indication: Glucose pharmaceutical formulations (oral tablets, injections) are indicated for caloric supply and carbohydrate supplementation in case of nutrient deprivation. It is also used in metabolic disorders such as hypoglycemia.

Associated Conditions: Arrhythmia, Caloric Deficit, Edema of the cerebrum, Hypoglycemia, Metabolic Alkalosis

Associated Therapies: Blood Specimen Collection, Electrolyte replacement, Nutritional supplementation, Parenteral Nutrition, Parenteral rehydration therapy, Plasmapheresis, Positive cardiac inotropic effect, Total parenteral nutrition therapy, Urine alkalinization therapy, Fluid and electrolyte maintenance therapy

Clinical Trials

The Relationship Between Stage of Diabetic Retinopathy and Retinal Blood Flow in Patients With IDDM During Euglycemic Clamp

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 1
Insulin
Retina
Regional Blood Flow

First Posted Date: 2008-12-23

Last Posted Date: 2008-12-23

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 64

Registration Number: NCT00814008

Locations: 🇦🇹
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria

Beta Cell Function in (Pre) Type 1 Diabetes

Phase 1

Conditions: Type 1 Diabetes

Interventions: Drug: glucose 20%

First Posted Date: 2008-12-01

Last Posted Date: 2013-12-30

Lead Sponsor: AZ-VUB

Target Recruit Count: 200

Registration Number: NCT00800085

Locations: 🇧🇪
UZ Brussels, Brussels, Belgium
🇧🇪
UZ Gent, Gent, Belgium
🇧🇪
UZ Leuven, Leuven, Belgium

and more 1 locations

Improving Glycogen Liver Content Will Improve Post-operative Liver Function in Patients Undergoing Major Liver Resections

Not Applicable

Completed

Conditions: Liver Function

Interventions: Drug: Intravenous normal saline (NS 0.9)
Drug: dextrose 10% (D10W ®) infusion
Drug: hyperinsulinemic normoglycemic clamp
Dietary Supplement: high calorie diet 35 kcal/kg

First Posted Date: 2008-10-17

Last Posted Date: 2010-04-01

Lead Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre

Target Recruit Count: 60

Registration Number: NCT00774098

Locations: 🇨🇦
Royal Victoria Hospital, Montreal, Quebec, Canada

Analgesic Efficacy of Oral Glucose in Preterm Neonates During Suctioning

Not Applicable

Conditions: Analgesia

Interventions: Drug: Glucose 20%
Drug: Aqua

First Posted Date: 2008-09-26

Last Posted Date: 2009-02-25

Lead Sponsor: University of Cologne

Target Recruit Count: 40

Registration Number: NCT00761059

Locations: 🇩🇪
Neonatology, Children's Hospital, University of Cologne, Cologne, Germany

Mechanism Underlying Beta-cell Failure in Obese African Americans With History of Hyperglycemic Crises

Not Applicable

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Intralipid 20%
Drug: Glucose infusion

First Posted Date: 2008-09-16

Last Posted Date: 2018-10-12

Lead Sponsor: Emory University

Target Recruit Count: 28

Registration Number: NCT00753142

Locations: 🇺🇸
Grady Memorial Hospital, Atlanta, Georgia, United States

Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.

Phase 2

Withdrawn

Conditions: Ovarian Cancer
Solid Tumor
Cancer

Interventions: Drug: IT-101 (15mg/m2/dose)
Drug: IT-101 (12mg/m2/dose)
Drug: 5% Dextrose (Placebo)

First Posted Date: 2008-09-16

Last Posted Date: 2020-06-12

Lead Sponsor: NewLink Genetics Corporation

Registration Number: NCT00753740

Locations: 🇺🇸
Schwartz Gynecologic Onclology, PLLC, Brightwaters, New York, United States
🇺🇸
Riverside Gynecology & Oncology, Newport News, Virginia, United States
🇺🇸
Decatur Memorial Hospital, Clinical Research Department/ Cancer Care Specialists of Illinois, Decatur, Illinois, United States

and more 4 locations